Emerging Companies

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...

Trucode: advancing nuclease-free, viral vector-independent gene therapy

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...

Cullgen: boosting the breadth of E3 ligases for protein degradation

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases. With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen...

Hesperos: uniting organs on a chip

Hesperos hopes to supplant animal models as the standard preclinical testing ground by designing reconfigurable, multi-organ chips to predict drug efficacy and toxicity early in development. The organ-on-a-chip company spun out of the Tissue Chip...

Tscan: Tracking down novel T cell targets

Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities. "Most targets have been discovered in a one-off fashion, notably by...

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...

A-Alpha Bio retools yeast mating for high throughput drug discovery

A-Alpha Bio is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles,...

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...

Owkin: machine learning with privacy protection

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions. Gilles Wainrib, Owkin’s co-founder and...

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....

Bringing CAR T to India

A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in India for about $50,000 per treatment. That cost, which...

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...

Limbix: A virtual treatment for the reality of depression

Limbix is using virtual reality to treat mental health conditions, starting with adolescent depression, where it could offer an alternative to medicating kids and the long wait lists for therapists. The company launched in 2016...

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...